The main issue is not even mentioned - cheap anti-HIV drugs require escape from patents and promotion of generic manufacturing to reduce costs to the level that poor countries can afford to buy or produce the necessary retrovirals.
> "Critical to the therapeutics market has been the role of generic drug manufacturers’ ability to supply low- and middle-income (LMIC) markets with off-patent and licensed products at a high volume and relatively low cost."
HIV patients in wealthy countries are a cash cow for the pharmaceutical industry, at least for as long as a permanent one-shot cure is not discovered, but there's no profit in making drugs for people who can't afford to pay for them. As Goldman Sachs noted, discovery of a cure would destroy the market. Isn't capitalism great?
https://academic.oup.com/cid/article/75/Supplement_4/S557/68...
> "Critical to the therapeutics market has been the role of generic drug manufacturers’ ability to supply low- and middle-income (LMIC) markets with off-patent and licensed products at a high volume and relatively low cost."
HIV patients in wealthy countries are a cash cow for the pharmaceutical industry, at least for as long as a permanent one-shot cure is not discovered, but there's no profit in making drugs for people who can't afford to pay for them. As Goldman Sachs noted, discovery of a cure would destroy the market. Isn't capitalism great?
https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patie...